CJC-1295 (No DAC) / Ipamorelin

Description

Overview

The combination of CJC-1295, a long-acting Growth Hormone Releasing Hormone (GHRH) analog, and Ipamorelin, a highly selective Growth Hormone Secretagogue (GHS), is commonly studied for its potential synergistic influence on endogenous growth hormone release. By engaging two distinct pathways—the GHRH receptor and the ghrelin (GHS-R1a) receptor—this blend provides researchers with a model for evaluating coordinated GH-axis stimulation.

Preclinical Research Background

CJC-1295 (GHRH Analog)

Research has shown that CJC-1295 may:

• Extend the half-life of GHRH signaling
• Increase pulsatile growth hormone release
• Elevate IGF-1 levels in experimental models
• Support anabolic and regenerative pathways
• Influence metabolic and endocrine function over prolonged durations

Ipamorelin (Selective GHS)

Preclinical studies suggest Ipamorelin may:

• Stimulate GH release without significant effects on cortisol or prolactin
• Activate GH secretagogue pathways through ghrelin receptor signaling
• Enhance recovery following musculoskeletal stress
• Support nutrient partitioning and metabolic balance
• Maintain a favorable endocrine profile compared to non-selective secretagogues

Rationale for Combination Research

Combining a GHRH analog with a GHS allows researchers to study two complementary mechanisms of GH release:

CJC-1295 may provide:

• Sustained GH-axis activity
• Increased baseline GH levels
• Support for long-term anabolic signaling

Ipamorelin may provide:

• Enhanced GH pulse amplitude
• Selective, receptor-driven GH release
• Minimal off-target hormonal stimulation

Together, research suggests the blend may:

• Increase the magnitude and frequency of GH pulses
• Promote IGF-1 elevation in animal models
• Support regenerative and metabolic pathways more effectively than either compound alone
• Offer insight into multi-pathway endocrine regulation

Areas of Emerging Scientific Interest

Current research continues to explore this combination in:

• Age-related GH decline and endocrine research
• Studies on muscle recovery, performance, and tissue repair
• Metabolic efficiency and body composition models
• Investigations involving bone density and connective tissue integrity
• Neuroendocrine and circadian rhythm signaling

Because of their synergistic roles, the CJC-1295 + Ipamorelin blend remains a key model for studying complex GH regulation.